[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of North Texas Health Science Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":97},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100477293","iht-for-mild-cognitive-impairment-100477293",false,"NCT05495087","IHT for Mild Cognitive Impairment","Intermittent Hypoxia Training: A Novel Therapy for Mild Cognitive Impairment","Inclusion Criteria:\n\n* Adult men and women ages 55 to 79 years old who have been diagnosed with MCI.\n* Must be willing to be assigned to either group: treatment or sham-treatment control.\n* Able to pay multiple visits to the lab for the proposed assessments.\n* Able to breathe moderately hypoxic air via an air-cushioned, disposable facemask.\n* To have controlled stabilized chronic conditions of at least 6 months duration, such as hypertension, coronary artery disease, diabetes or metabolic disease, chronic bronchitis, degenerative osteoporosis or arthritis and\u002For other aging-related chronic conditions.\n* Must be depression-free at the time of enrollment.\n* Must have arterial oxygen saturation at or above 95% and cerebral tissue oxygenation at or above 50% at rest.\n* Woman subject must be post-menopausal.\n\nExclusion Criteria:\n\n* Unwilling to sign a written consent to participate in this double-blinded placebo-controlled phase I trial.\n* Diagnosed with AD-dementia or have impaired independent daily functioning; with MMSE \\\u003C20 and\u002For CDR ≥1.\n* Unable to visit the lab independently.\n* Claustrophobic to facemask and hyper-reactive to hypoxia exposure.\n* Expecting any major surgery or transplant.\n* Have un-controlled chronic conditions including systolic-diastolic pressures over 150\u002F90 mmHg with medications, diabetes, chronic renal failure (based on the medical history questionnaire), recurrent chest pain, seizures or epilepsies, moderate to severe carotid stenosis or calcification, brain aneurysm, uncontrolled allergic rhinitis, pulmonary fibrosis, emphysema, cancer, infectious disease, atrial fibrillation, regular pre-mature ventricular contractions, myocardial ischemia or infarct, 2nd or 3rd degree atrio-ventricular blockade.\n* Have severe head injury or traumatic brain injury, stroke (hemorrhagic and\u002For ischemic).\n* Have currently diagnosed depression.\n* Currently have COVID-19.\n* Have any metallic implants or who are claustrophobic.\n* Currently participating in any interventional study and\u002For have been previously exposed to hypoxia, such as residing more than two months at altitudes above 5000 ft. within the past 3 years or previously participated in a hypoxia training study.","ALL","55 Years","79 Years",{"count":20,"type":21},66,"ESTIMATED","INTERVENTIONAL",[24],"NA","This phase I clinical trial will examine the safety and efficacy of intermittent hypoxia training (IHT) for up to 12 weeks to treat subjects with mild cognitive impairment (MCI).",[27,28],"Mild Cognitive Impairment","Memory Impairment",[30],"intermittent hypoxia training or preconditioning","RECRUITING","2026-04-23",{"date":34,"type":35},"2026-04-29","ACTUAL",{"date":37,"type":35},"2023-02-27",{"date":39,"type":21},"2026-04-30",{"name":41,"class":42},"University of North Texas Health Science Center","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100518060","phase-1-targeting-endoplasmic-reticulum-stress-in-human-hypertension-100518060","NCT06025630","Targeting Endoplasmic Reticulum Stress in Human Hypertension","Inclusion Criteria:\n\n1. 18 to 80 years of age\n2. No tobacco\u002Fnicotine use within preceding 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches)\n3. Systolic blood pressure \\\u003C140 mmHg; diastolic blood pressure \\\u003C90 mmHg (obtained at the Screening and Familiarization Visit)\n4. Normal 12-lead ECG (obtained at the Screening and Familiarization Visit and reviewed by a board-certified physician)\n5. Normal clinical results from a medical exam reviewed by a board-certified physician (e.g., General Health Questionnaire obtained at the Screening and Familiarization Visit)\n6. Body mass index (BMI) \\\u003C35 unless athletic\u002Fmuscular build; calculation = body weight (kg)\u002Fheight (m2);\n7. Females only: documentation of a negative pregnancy test prior to the familiarization and experimental sessions unless post-menopausal\n\nExclusion Criteria:\n\n1. Not meeting the defined age criteria\n2. Body mass index (BMI) \\>35 unless athletic\u002Fmuscular build; calculation = body weight (kg)\u002Fheight (m2)\n3. Any tobacco\u002Fnicotine use within the last 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches)\n4. Positive pregnancy test\n5. Females with an erratic\u002Firregular menstrual cycle\n6. Females who are breastfeeding\n7. Women who are prescribed a continually releasing hormonal contraceptive (e.g. NuvaRingTM or other hormone releasing vaginal rings, Depo Provera shot, or birth control implants such as Nexplanon)\n8. Subjects who weigh less than 80 lbs.\n9. Use of prescription drugs, non-prescription drugs, dietary supplements or herbal medicines known to alter vascular function unless cleared prior to the study\n10. Use of beta blockers\n11. Daily use of bronchodilators\n12. Use of anti-coagulant therapy\n13. Implanted medical devices (e.g. cardiac pacemaker)\n14. Current or past history of hyperthyroidism, or other thyroid hormone-related disease\n15. Current use of hormone replacement therapy (e.g., estrogen, testosterone)\n16. HbA1c \\>5.6\n17. Resting systolic blood pressure of \\\u003C100 mmHg; \\>140mmHg or diastolic blood pressure \\>90mmHg\n18. Abnormal 12-lead ECG or uncontrolled heart rhythm issues causing symptoms, or an unstable blood pressure\n19. History of cerebrovascular abnormalities (e.g., prior stroke, transient ischemic attacks, epilepsy)\n20. Known history of atherosclerosis of the carotid arteries (i.e., plaque formation)\n21. History of concussion and or other loss of consciousness within the preceding 30 days\n22. Autonomic dysfunction (e.g., Shy-Drager Syndrome, Bradbury-Eggleston syndrome, sinus arrhythmia, idiopathic orthostatic hypotension, fainting disorder)\n23. Respiratory illnesses (e.g., chronic asthma (including exercise-induced asthma), Chronic Obstructive Pulmonary Disease, Reactive Airway Disease)\n24. Any prior history of anaphylaxis, not just prior reactions to the materials used in this study\n25. Severe phobia of needles\n26. Latex allergy aa) Known allergies or sensitivities to substances used in the study (e.g., Lidocaine HCL, sodium nitroprusside, acetylcholine, phentolamine, L-NAME, TUDCA, or related drugs) bb) Donated blood within the last 60 days cc) History or family history of abnormal blood clotting, clots in deep veins in the legs or pelvis, or blood clots to the lungs dd) History of alcohol or drug abuse which inhibits the subject's ability to complete this study ee) Individuals who have had mastectomies ff) History of methemoglobinemia gg) Current diagnosis of anemia hh) Current Fever (oral temp \\>99.5 °F\u002F 37.5 °C) ii) Current use of PDE3 inhibitors (e.g., Viagra) or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat), or unwillingness to withhold medication for 2 weeks prior to laboratory testing jj) Current diagnosis of cancer kk) Cardiac surgery or cardiac events (e.g., coronary artery bypass graft surgery, myocardial infarction, heart failure) ll) Diagnosis of neurological disease or cognitive dysfunction","18 Years","80 Years",{"count":53,"type":21},70,[55,56],"PHASE1","PHASE2","There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in humans with hypertension.",[59],"Hypertension",[61,62,63],"high blood pressure","tauroursodeoxycholic acid (TUDCA)","endoplasmic reticulum","2025-03-24",{"date":66,"type":35},"2025-03-28",{"date":68,"type":35},"2023-08-15",{"date":70,"type":21},"2028-12-31",{"name":41,"class":42},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":16,"minAge":81,"maxAge":18,"enrollmentInfo":82,"targetDuration":84,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100428030","precision-pain-research-registry-100428030","NCT04853732","PRECISION Pain Research Registry","Pain Registry for Epidemiological, Clinical, and Interventional Studies and Innovation","PRECISION","Inclusion Criteria:\n\n* Must reside within the contiguous 48 United States or District of Columbia\n* Must provide a valid, government-issued identification with photo and birthdate\n* Must have Internet access or telephone service to communicate with registry staff\n* Must have sufficient English language proficiency to complete case report forms independently or with assistance from registry staff\n* Must have a primary care physician or other physician who regularly provides health care\n* Must provide the name, dose, and frequency of use of all current medications\n* Case participants must have chronic low back pain\n* Control participants must be free of any chronic pain and may include healthy volunteers\n\nExclusion Criteria:\n\n* Must not be pregnant\n* Must not reside in an institutional facility",true,"21 Years",{"count":83,"type":21},10000,"36 Months","OBSERVATIONAL","The PRECISION Pain Research Registry enrolls participants with chronic low back pain (cases) and participants who are free of chronic pain (controls) to study the epidemiology and management of chronic pain. The vision of the registry is to conduct research to provide a future for all unbounded by pain.",[88],"Chronic Low Back Pain","2024-01-11",{"date":91,"type":35},"2024-01-16",{"date":93,"type":35},"2016-04",{"date":95,"type":21},"2030-12",{"name":41,"class":42},""]